Page 43 - Read Online

cases. Human epithelial growth factor receptor-2 gene in primary hepatocellular carcinomas by somatic alterations
[35]
(HER2) and topoisomerase II alpha (TOP2A) have been 4. involving exon 3. Cancer Res 1998;58:2524-7.
Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, Pawlik
identified to be co-amplified in breast and some TM, Daniel HD, Kannangai R, Offerhaus GJ, Velculescu VE, Wang
other cancers, but the HER2 gene status and HER2 L, Zhou S, Vogelstein B, Hruban RH, Papadopoulos N, Cai J,
[36]
protein expression in HCC has been controversial. Torbenson MS, Kinzler KW. Inactivating mutations of the chromatin
[37]
remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet
However, no correlation was shown between TOP2A 2011;43:828-9.
amplification and TOP2A overexpression in HCC. [38] 5. Yakicier MC, Irmak MB, Romano A, Kew M, Ozturk M. Smad2
and Smad4 gene mutations in hepatocellular carcinoma. Oncogene
Gene deletion of tumor suppressor genes in certain 6. 1999;18:4879-83.
Soung YH, Lee JW, Kim SY, Sung YJ, Park WS, Nam SW, Kim SH,
regions of chromosomes also plays a crucial role Lee JY, Yoo NJ, Lee SH. Caspase-8 gene is frequently inactivated by
in the pathogenesis of cancer. CDKN2A is a tumor the frameshift somatic mutation 1225_1226delTG in hepatocellular
suppressor gene that encodes for p16 and p14ARF. In 7. carcinomas. Oncogene 2005;24:141-7.
Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo
a recent whole-genome sequencing study, CDKN2A A, Katz A, Bruix J, Bioulac-Sage P, Martignetti JA, Friedman SL.
deletion was identified in 10.2% HCC cases. Protein Frequent inactivation of the tumor suppressor Kruppel-like factor 6
[2]
tyrosine phosphatase, receptor type D, a tumor (KLF6) in hepatocellular carcinoma. Hepatology 2004;40:1047-52.
suppressor gene, which was previously identified 8. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH,
Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH. Germ
to be frequently deleted in several cancers, [39-41] was line p53 mutations in a familial syndrome of breast cancer, sarcomas,
also identified with homozygous deletion in human and other neoplasms. Science 1990;250:1233-8.
HCCs. [42] 9. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53
mutations and hepatocellular carcinoma: insights into the etiology
and pathogenesis of liver cancer. Oncogene 2007;26:2166-76.
PROSPECTS 10. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P,
Olivier M. Impact of mutant p53 functional properties on TP53
In summary, multiple lines of evidence have shown mutation patterns and tumor phenotype: lessons from recent
developments in the IARC TP53 database. Hum Mutat 2007;28:622-
that the genetic and genomic alterations play 9.
important roles in the development and progression 11. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad
of HCC. The next generation sequencing of genomic IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clément B,
Balabaud C, Chevet E, Laurent A, Couchy G, Letouzé E, Calvo
DNA provides the possibility that more novel genetic F, Zucman-Rossi J. Integrated analysis of somatic mutations and
and genomic alterations may be discovered and focal copy-number changes identifies key genes and pathways in
may provide new insights for understanding of the hepatocellular carcinoma. Nat Genet. 2012;44:694-8.
pathogenesis of HCC. However, further studies on the 12. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the
development and treatment of hepatocellular carcinoma. Oncogene
role of genetic mutation and genomic imbalances in 2010;29:4989-5005.
the pathogenesis of HCC, as well as related functional 13. Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, Zhu ZD, Zhou
and mechanistic studies are also urgently needed. B, Liu XY, Liu RF, Fei QL, Chen H, Cai B, Zhou B, Xiao HS, Qin
LX, Han ZG. Exome sequencing of hepatitis B virus-associated
hepatocellular carcinoma. Nat Genet. 2012;44:1117-21.
Financial support and sponsorship 14. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen
This work is supported by a grant from the Beijing HH, Aoki M, Hosono N, Kubo M, Miya F, Arai Y, Takahashi H,
Natural Science Foundation (7132058). Shirakihara T, Nagasaki M, Shibuya T, Nakano K, Watanabe-Makino
K, Tanaka H, Nakamura H, Kusuda J, Ojima H, Shimada K, Okusaka
T, Ueno M, Shigekawa Y, Kawakami Y, Arihiro K, Ohdan H, Gotoh
Conflicts of interest K, Ishikawa O, Ariizumi S, Yamamoto M, Yamada T, Chayama
There are no conflicts of interest. K, Kosuge T, Yamaue H, Kamatani N, Miyano S, Nakagama H,
Nakamura Y, Tsunoda T, Shibata T, Nakagawa H. Whole-genome
sequencing of liver cancers identifies etiological influences on
REFERENCES mutation patterns and recurrent mutations in chromatin regulators.
Nat Genet 2012;44:760-4.
1. Theise ND, Chen CJ, Kew MC. Liver cancer. In: Stewart B, Wild C, 15. Xie HJ, Bae HJ, Noh JH, Eun JW, Kim JK, Jung KH, Ryu JC,
editors. World Cancer Report 2014. Lyon: International Agency for Ahn YM, Kim SY, Lee SH, Yoo NJ, Lee JY, Park WS, Nam
Research on Cancer; 2014. p. 577-93. SW. Mutational analysis of JAK1 gene in human hepatocellular
2. Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, Gao H, Hao K, carcinoma. Neoplasma 2009;56:136-40.
Willard MD, Xu J, Hauptschein R, Rejto PA, Fernandez J, Wang 16. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability – an
G, Zhang Q, Wang B, Chen R, Wang J, Lee NP, Zhou W, Lin Z, evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010;11:220-8.
Peng Z, Yi K, Chen S, Li L, Fan X, Yang J, Ye R, Ju J, Wang K, 17. Bunz F, Fauth C, Speicher MR, Dutriaux A, Sedivy JM, Kinzler KW,
Estrella H, Deng S, Wei P, Qiu M, Wulur IH, Liu J, Ehsani ME, Vogelstein B, Lengauer C. Targeted inactivation of p53 in human
Zhang C, Loboda A, Sung WK, Aggarwal A, Poon RT, Fan ST, Wang cells does not result in aneuploidy. Cancer Res 2002;62:1129-33.
J, Hardwick J, Reinhard C, Dai H, Li Y, Luk JM, Mao M. Whole- 18. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas
genome sequencing identifies recurrent mutations in hepatocellular A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B,
carcinoma. Genome Res 2013;23:1422-33. Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD. Activation
3. Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Sasaki Y, Imaoka S, of the DNA damage checkpoint and genomic instability in human
Murata M, Shimano T, Nakamura Y. Activation of the beta-catenin precancerous lesions. Nature 2005;434:907-13.

34 Hepatoma Research | Volume 2 | Issue 2 | February 29, 2016